Long intergenic non-protein coding RNA 1226 (LINC01226)

Long intergenic non-protein coding RNA 1226 (LINC01226) is a long non-coding RNA transcribed from a region upstream of the SERINC2 gene, also referred to as SEELA2 or SERINC2-ELA2[1][2][3][4]. It functions as an enhancer-associated RNA (eRNA) and binds histone components to activate the expression of SERINC2 in cis, which is linked to lipid metabolism and cancer progression, particularly in leukemia[2]. In gastric cancer, overexpression of LINC01226 promotes tumor growth, migration, and metastasis by binding to the protein STIP1, disrupting the STIP1-HSP90 complex, stabilizing β-catenin, and activating the Wnt/β-catenin signaling pathway[3][4][6][8]. High levels of LINC01226 correlate with poor cancer prognosis and aggressive tumor features. It is considered a potential therapeutic target and oncogenic driver, but no clinical drugs specifically target it at present.

Other names

SEELA2SERINC2-ELA2

As a drug target, mechanisms would be inhibition of lncRNA function to down-regulate downstream oncogenic targets; in research contexts: siRNA or antisense oligonucleotides can knock down LINC01226[2][3]. No small molecule or clinical drug-based inhibitors described as of current knowledge.